| Trial ID: | L5552 |
| Source ID: | NCT05098470
|
| Associated Drug: |
Metformin
|
| Title: |
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Metformin|DRUG: Insulin Glargine|DRUG: Dorzagliatin
|
| Outcome Measures: |
Primary: Contribution of gluconeogenesis (GNG) to endogenous glucose production (EGP), Ratio of GNG to total EGP, 8 weeks | Secondary: Contribution of glycogenolysis (GLY) to EGP, Ratio of GLY to total EGP, 8 weeks|Glucokinase activity, UDP glucose flux, 8 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Alabama at Birmingham | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER
|
| Start Date: |
2022-03-07
|
| Completion Date: |
2026-03-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-09-26
|
| Locations: |
Rita Basu, Birmingham, Alabama, 35294, United States|University of Virginia, Charlottesville, Virginia, 22908, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05098470
|
